Clinical trials
Non-Hodgkin Lymphoma clinical trials
Below are recruiting non-hodgkin lymphoma clinical trials, each written for real people, not researchers. We’re tracking 306 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07195799RecruitingPhase 2
Linperlisib with CPT for relapsed or refractory non-Hodgkin lymphoma
This trial tests a combination of drugs (linperlisib, cyclophosphamide, prednisone, and thalidomide) for people with certain types of non-Hodgkin lymphoma that have come back or not responded to previous treatments. It aims to see if this combination can help control the disease.
Nanjing, JiangsuAges 18 years+ - NCT07202052RecruitingPhase 2/Phase 3
Antibiotics or immunoglobulin for infections in blood cancer
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Adelaide, South AustraliaAges 18 years+ - NCT07192471RecruitingPhase 1
Study of KK2223 for T-cell lymphoma after prior treatments
This study tests a new drug called KK2223 for people with certain types of T-cell lymphoma (PTCL or CTCL) that have not responded to previous treatments. The goal is to find out if the drug is safe and if it helps shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Gilbert, ArizonaAges 18 years+ - NCT07188090RecruitingPhase 2
Mozobil for stem cell transplant study
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07168980RecruitingPhase 2/Phase 3
Chemotherapy plus rituximab for aggressive B-cell lymphoma in kids
This trial tests whether adding rituximab to standard chemotherapy works better for children and teens with aggressive B-cell non-Hodgkin lymphoma. It may be a good option if your child's cancer cells have the CD20 protein and they haven't been treated with rituximab before.
Shanghai, Shanghai MunicipalityAges Up to 18 years - NCT07147621Recruiting
Chemotherapy and thinking changes in blood cancer treatment
This study looks at whether chemotherapy for blood cancers like leukemia and lymphoma can affect thinking, memory, or concentration. It compares patients to a close family member or friend to see if any changes are related to the treatment.
Angers, Maine et LoireAges 18 years+ - NCT07121946RecruitingPhase 1
Safety study of LTZ-301 for non-Hodgkin lymphoma
This trial tests a new drug, LTZ-301, in people with non-Hodgkin lymphoma whose cancer has come back or not responded to at least two prior treatments. The main goal is to see if LTZ-301 is safe and how the body handles it.
Duarte, CaliforniaAges 18 years+ - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Irvine, CaliforniaAges 18 years+ - NCT07114367RecruitingPhase 1
NB02 for relapsed non-Hodgkin's lymphoma
This trial tests a new oral drug (NB02) for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two prior treatments. It aims to see if the drug can shrink tumors and control the disease.
HwasunAges 19–80 - NCT06925464RecruitingPhase 1/Phase 2
Modified immune cells for T-cell lymphoma
This trial tests a new treatment where your own immune cells are modified to find and attack CD7-positive T-cell lymphoma cells. It is for people whose lymphoma has not responded to standard treatments.
Beijing, Beijing MunicipalityAges 14–70 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT07097363RecruitingPhase 2
Epcoritamab plus chemo for aggressive B-cell lymphoma
This trial tests a new drug, epcoritamab, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with aggressive B-cell non-Hodgkin lymphoma that hasn't been treated before or has had only one round of chemo. It aims to see if this combination works better against certain high-risk types of lymphoma.
Seattle, WashingtonAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07093411RecruitingEarly Phase 1
Targeted cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is designed for patients whose lymphoma has not responded to or has returned after previous treatment, and who cannot or choose not to receive standard CAR-T therapy.
HefeiAges 18–75 - NCT07082803RecruitingPhase 1
TLN-121 for relapsed or refractory lymphoma
This trial tests an investigational drug (TLN-121) for people with certain types of lymphoma that have come back or stopped responding to previous treatments. It aims to see if the drug can control the cancer and how safe it is.
Palo Alto, CaliforniaAges 18 years+ - NCT03117036Recruiting
Study follows people with Hodgkin or non-Hodgkin lymphoma
This study enrolls adults with Hodgkin or non-Hodgkin lymphoma who plan to receive chemotherapy aimed at cure. It may help doctors better understand outcomes and how lymphoma care is managed over time.
SeoulAges 20–90 - NCT07073833RecruitingPhase 1
IBR900 cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new cell therapy (IBR900) for people with a type of B-cell lymphoma that has come back or not responded to prior treatments. The therapy uses your own immune cells to target and kill the cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07072169RecruitingPhase 1
Testing an mRNA therapy for relapsed B-cell lymphoma
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07059741Recruiting
Radiation, stem cell transplant, and CAR-T for aggressive B-cell lymphoma
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
Suzhou, JiangsuAges 18 years+ - NCT06323525RecruitingPhase 1/Phase 2
Modified CAR-T cell therapy for relapsed/refractory B-cell lymphoma
This trial tests a new type of CAR-T cell therapy for people with certain B-cell lymphomas that have come back or not responded to treatment. The CAR-T cells are made from a donor and are genetically edited to possibly work better and last longer.
Beijing, Beijing MunicipalityAges 18–70 - NCT07053670RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
Wuhang, HubeiAges 18–75 - NCT07020533RecruitingPhase 1
CMV vaccine for stem cell transplant recipients
This trial tests a vaccine designed to boost immunity against CMV (a common virus) and prevent active CMV infection in people receiving a half-matched stem cell transplant. It may help protect you from CMV-related complications after transplant.
Duarte, CaliforniaAges 18–75 - NCT07022964RecruitingPhase 1/Phase 2
CD5 CAR T-cell therapy for relapsed or refractory T-cell lymphoma
This trial tests a new treatment called CD5 CAR T-cell therapy for people with T-cell lymphoma that has come back or not responded to standard treatments. It offers a possible option when other therapies like chemotherapy or stem cell transplant are no longer working.
BeijingAges 14–70
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-hodgkin lymphoma?
- Yes. Clin2 currently lists 306 recruiting non-hodgkin lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-hodgkin lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.